APIM Therapeutics announces getting in more financing.

APIM Therapeutics, a Ventac Partners portfolio company, announced that it has completed a new financing round by existing and new investors. This financing will enable the company to finalize preclinical development of ATX-101 aiming to file two clinical trial applications in late 2015.